Key result
Chemotherapy in women with breast cancer induced dyslipidemia, characterized by a significant increase in LDL-C after anthracycline treatment and a significant decrease in HDL-C and total cholesterol after completing both anthracycline and taxane regimens.
Why the study?
To investigate the effect of doxorubicin, cyclophosphamide, and taxane chemotherapy on the lipid profile in Iraqi patients with breast cancer.
Does chemotherapy with doxorubicin, cyclophosphamide, and taxanes alter the serum lipid profile in women with primary breast cancer?
Cohort (n=56)
Yes
Does chemotherapy with doxorubicin, cyclophosphamide, and taxanes alter the serum lipid profile in women with primary breast cancer?
Absolute Event Rate: 168.3% vs 193.75%
p-value: p=<0.05
Chemotherapy regimens containing anthracyclines and taxanes induce significant pro-atherogenic changes in the lipid profile of young women with breast cancer, notably increasing LDL-C and decreasing HDL-C.
Lipid monitoring may be prudent during anthracycline-taxane chemotherapy; leaves open long-term cardiovascular risk in breast cancer survivors.
Objective: To investigate the effect of doxorubicin, cyclophosphamide and taxane chemotherapy on thelipid profile in Iraqi patients with breast cancer.Method: This cohort prospective study was carried out at the Biochemistry Department, Baghdad Collegeof Medical Sciences, and at the Oncology Clinic, Oncology Teaching Hospital, Baghdad, Iraq, during theperiod from May 2019 to October 2019. It included 56 women with regular menstrual cycle (25-45 years)classified into 3 groups: GI: 29 women with primary breast cancer (before starting chemotherapy), GII:the same 29 women of GI who were finished 4 cycles of anthracycline chemotherapy (course 1) and GIII:which involved another 27 women who had finished both courses of chemotherapy, (course 1) and 4 cyclesof taxanes (course 2). Serum cholesterol, LDL, HDL and TG were measured using colorimetric method.Results: The results of the present study showed that the (mean±SEM) of the serum cholesterol wasdecreased significantly (p<0.05) in GIII compared to GI and highly significantly (p<0.01) compared to GII.While, the serum HDL level was significantly (p<0.05) lower in GIII compared to GI. Concerning the serumLDL level, it was increased significantly (p<0.05) in GII compared to both GI and GIII. While; the serumTG level shows no significant difference between all groups.Conclusion: Iraqi women with breast cancer had an abnormal state of dyslipidemia that become worsenedafter chemotherapy.
No takes yet. Share an insight, caveat, or question.
Zainab Nazar Hasan Anber (2020) conducted a cohort in Primary breast cancer (n=56). Chemotherapy (anthracycline and taxane regimens) vs. Before starting chemotherapy (baseline) was evaluated on Serum cholesterol (mg/dl) after full chemotherapy regimen (p=<0.05). Chemotherapy in women with breast cancer induced dyslipidemia, characterized by a significant increase in LDL-C after anthracycline treatment and a significant decrease in HDL-C and total cholesterol after completing both anthracycline and taxane regimens.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: